Format

Send to

Choose Destination
Adv Colloid Interface Sci. 2018 Jan;251:44-54. doi: 10.1016/j.cis.2017.12.002. Epub 2017 Dec 8.

Nanotherapy for Alzheimer's disease and vascular dementia: Targeting senile endothelium.

Author information

1
Cavitation-Control Technology Inc., Farmington, CT 06032, USA. Electronic address: cavcon@ntplx.net.

Abstract

Due to the complexity of Alzheimer's disease, multiple cellular types need to be targeted simultaneously in order for a given therapy to demonstrate any major effectiveness. Ultrasound-sensitive coated microbubbles (in a targeted lipid nanoemulsion) are available. Versatile small molecule drug(s) targeting multiple pathways of Alzheimer's disease pathogenesis are known. By incorporating such drug(s) into the targeted "lipid-coated microbubble" [LCM]/"nanoparticle-derived" [ND] (or LCM/ND) nanoemulsion type, one obtains a multitasking combination therapeutic for translational medicine. This multitasking therapeutic targets cell-surface scavenger receptors (mainly class B type I), or SR-BI, making possible for various Alzheimer's-related cell types to be simultaneously searched out for localized drug treatment in vivo. Besides targeting cell-surface SR-BI, the proposed LCM/ND-nanoemulsion combination therapeutic(s) include a characteristic lipid-coated microbubble [LCM] subpopulation (i.e., a stable LCM suspension); such film-stabilized microbubbles are well known to substantially reduce the acoustic power levels needed for accomplishing temporary noninvasive (transcranial) ultrasound treatment, or sonoporation, if additionally desired for the Alzheimer's patient.

KEYWORDS:

Alzheimer's disease; Dementia; Drug targeting; Nanoemulsion; Scavenger receptors; Sonoporation

PMID:
29274774
DOI:
10.1016/j.cis.2017.12.002
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center